Dautzenberg B, Castellani P, Truffot-Pernot CH, Leng B, Sassella D; International Conference on AIDS.
Int Conf AIDS. 1996 Jul 7-12; 11: 117 (abstract no. Mo.B.1359).
Pneumologie-G.H. Pitie-Salpetriere, Paris, France. Fax: (33) 1 44 23 92 55.
Objective: To determine activity of rifabutin as a single agent in the treatment of M.avium bacteraemia in AIDS patient. Methods: Rifabutin 600 mg/d was randomly compared to placebo in a doubleblind 14 days trial in AIDS patients with culture proven M.avium bacteraemia. After 14 days, an open treatment combination was proposed. All subjects gave written informed consent. Two quantitative blood cultures were performed at D0, D3, D7, D10 and D14. Only patients with positive blood culture at D0 were eligible. Main endpoint was bacteriological success, defined as a reduction in the number of colony forming units of M.avium organisms/ml of blood by factor greater than or equal to0.5 log or a negative blood culture. Results: A total of 36 patients were randomized. Because of negative blood culture at baseline (n = 10) or other reasons (n = 3), only 23 patients were assessed at the endpoint (10 received rifabutin and 13 placebo) median CD4 was 4.5/mm3 in rifabutin group and 11/mm3 in placebo group: Bacteriological success was recorded in 7/10 (70 %) of patients assigned to placebo (p = 0.002). Conclusion: Rifabutin as a single agent is active against M.avium and can contribute to treatment regimens for M.avium bacteraemia in AIDS patients.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Bacteremia
- Clinical Trials as Topic
- Humans
- Physical Examination
- Placebos
- Rifabutin
- Treatment Outcome
- methods
Other ID:
UI: 102217321
From Meeting Abstracts